TY - JOUR
TI - Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
AU - Tsivgoulis, G.
AU - Katsanos, A.H.
AU - Voumvourakis, K.
AU - Hadjigeorgiou, G.M.
AU - Heliopoulos, I.
AU - Karapanayiotides, T.
AU - Papathanasopoulos, P.
AU - Kilidireas, C.
AU - Grigoriadis, N.
JO - Multiple Sclerosis and Related Disorders
PY - 2018
VL - 21
TODO - null
SP - 117-119
PB - Elsevier B.V.
SN - 2211-0348
TODO - 10.1016/j.msard.2018.03.010
TODO - alemtuzumab;  beta1a interferon;  glatiramer;  natalizumab;  ocrelizumab;  glatiramer, clinical effectiveness;  drug efficacy;  human;  immunotherapy;  Letter;  methodology;  monotherapy;  multiple sclerosis;  randomized controlled trial (topic);  therapy effect;  treatment outcome;  multiple sclerosis, Glatiramer Acetate;  Humans;  Multiple Sclerosis;  Multiple Sclerosis, Relapsing-Remitting
TODO - null
ER -